180 Life Sciences Corporate Media Kit

16 Large Market Opportunity for Early Dupuytren’s Disease Estimated future worldwide market for Dupuytren’s is a multi-billion dollar one (1) All current treatments for Dupuytren's are for LATE stage disease • 4% of the EU & US population suffer from Dupuytren’s disease (1,2) • Assume ~25% of these (1% total) are symptomatic & require treatment (3) • Potential patients in the U.S. (1% of 315M) = 3M patients • Conservatively assume 25% of symptomatic patients get treatment (4) Geography Population Assumptions Number of Patients Market Size (assuming $1,000 treatment per patient)(5) USA 1% x 315M ~ 3.0M patients $3.0B EU 50% of USA ~ 1.5M patients $1.5B (1) Hindocha S, McGrouther DA, Bayat A (2009) Hand (NY) 4(3):256-69. (2) Lanting et al. (2014) PRS 133: 593-603 (3) Nanchahal J, et al. (2017) Wellcome Open Res 2:37 (4) Layton T & Nanchahal J (2019) F1000Res Feb 28;8:F1000 Faculty Rev-231 (5) Based on current price of comparable anti-TNF treatments 180 Life Sciences Corp. www.180lifesciences.com Q4 2020